Evidence map›Paper›PMID 31931292›Full record

ArticleRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology2020

Lymphopenia during radiotherapy in patients with oropharyngeal cancer.

Sweet Ping Ng, Houda Bahig, Amit Jethanandani, Courtney Pollard, Joel Berends, Erich M Sturgis, Faye M Johnson, Baher Elgohari, Hesham Elhalawani, David I Rosenthal and 7 more

Open access · greenAbstract read
In one paragraph

Article in Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Correlation of dynamic blood dose with clinical outcomes in radiotherapy for head-and-neck cancer.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2025
    Article
  8. Article
  9. Haematological and renal toxicity of radiation therapy in neuroblastoma paediatric patients.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Radiation-induced lymphopenia: the main aspects to consider in immunotherapy trials for endometrial and cervical cancer patients.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020
    Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 3 countries.

Sweet Ping NgDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia. Electronic address: sweet.ng@petermac.org.
Houda BahigDepartment of Radiation Oncology, Centre Hospitalier de l'Universite de Montreal, Canada.
Amit JethanandaniDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Courtney PollardDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Joel BerendsDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Erich M SturgisDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA.
Faye M JohnsonDepartment of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Baher ElgohariDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Hesham ElhalawaniDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
David I RosenthalDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Heath D SkinnerDepartment of Radiation Oncology, UPMC Hillman Cancer Centers, Pittsburgh, USA.
G Brandon GunnDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Jack PhanDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Steven J FrankDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Abdallah S R MohamedDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Clifton D FullerDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Adam S GardenDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: agarden@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USCentre Hospitalier de l’Université de Montréal · CAUPMC Hillman Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Targeting the p53 pathway for reversal of oral premalignancyP50CA097007 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MYERS, JEFFREY NICHOLAS · 2002 to 2012
$26.1M
Paul Calabresi Clinical Oncology AwardK12CA088084 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI David S. Hong, Scott Kopetz · 2000 to 2026
$14.0M
Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Establish Objective Clinical Outcome Measures for Mandibular OsteoradionecrosisR01DE025248 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LAI, STEPHEN Y · 2016 to 2020
$2.9M
SMART-ACT: Spatial Methodologic Approaches for Risk Assessment and Therapeutic Adaptation in Cancer TreatmentR01CA214825 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI CANAHUATE, GUADALUPE, FULLER, CLIFTON DAVID · 2017 to 2019
$1.1M
Fellow and Resident Radiation Oncology iNtensive Training in Imaging and Informatics to Empower Research Careers (FRONTI2ER)R25EB025787 · NIBIB · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DAS, PRAJNAN, FULLER, CLIFTON DAVID · 2018 to 2022
$535k
Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Establish Objective Clinical Outcome Measures for Mandibular OsteoradionecrosisR56DE025248 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LAI, STEPHEN Y · 2015 to 2015
$470k
NCI NIH HHS K12 CA088084NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA097007NCI NIH HHS R01 CA214825NIBIB NIH HHS R25 EB025787NIDCR NIH HHS R01 DE025248NIDCR NIH HHS R56 DE025248
6 · The paper itself

Abstract

PURPOSE/

objectiveRadiation-induced lymphopenia has been associated with poor survival outcomes in certain solid tumors such as esophageal, lung, cervical and pancreatic cancers. We aim to determine the effect of treatment-related lymphopenia during radiotherapy on outcomes of patients with oropharyngeal cancer. MATERIALS/

methodsA retrospective analysis of all patients who completed definitive radiotherapy for oropharyngeal cancer at The University of Texas MD Anderson Cancer Center and had blood counts taken during radiotherapy from 2002 to 2013 were included. Patient, tumor and treatment characteristics, clinical outcomes and lymphocyte counts during radiotherapy were recorded. Lymphopenia was graded according to the CTCAE v4.0. Survival rates were estimated using the Kaplan-Meier method and compared with log-rank tests.

results850 patients were evaluated. The median age was 57 years. The majority of the cohort had p16/HPV-positive disease (71%), 8% had HPV-negative disease and 21% were unknown. The median radiation total dose was 70 Gy. 45% of patients had induction chemotherapy, and 87% had concurrent chemotherapy. 703 (83%) patients developed ≥grade 3 (G3) lymphopenia and 209 (25%) had grade 4 (G4) lymphopenia during radiotherapy. The median follow-up was 59 months; the 5-year overall survival rate was 81%. There were no significant differences in overall survival rates nor in disease control rates, in those who developed G3/G4 lymphopenia compared with those who did not. No significant effect of lymphopenia on survival was observed when analyzed according to p16/HPV status.

conclusionIn this large cohort of patients with oropharyngeal cancer, the development of lymphopenia during radiotherapy did not impact outcomes.

Indexed as

LymphopeniaOropharyngeal NeoplasmsHumansLymphocytesMiddle AgedRetrospective StudiesSurvival RateLymphopeniaOropharyngeal cancerRadiotherapy

Identifiers

PMID31931292
PMCPMC7502182
OpenAlexW2999716878

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.